Moderna, Inc. - Common Stock (MRNA)
25.14
-0.59 (-2.29%)
NASDAQ · Last Trade: Apr 4th, 9:48 AM EDT
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen (NASDAQ:AMGN).
Via StockStory · April 3, 2025
Via The Motley Fool · April 3, 2025
The sector's recent slide follows Peter Marks' resignation last week as the Food and Drug Administration's top vaccine regulator following a clash with Kennedy.
Via Stocktwits · April 2, 2025
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.
Via Chartmill · April 1, 2025
US Markets continued to witness volatility on Monday as President Donald Trump's 'Liberation Day' fast approaches, bringing a volley of tariffs across products, industries, allies, and adversaries. Leading analysts and experts have since urged the President to reconsider his trade policy stance.
Via Benzinga · March 31, 2025
The stock market faced a challenging day as risk sentiment remained under pressure on Wall Street. The S&P 500 experienced a volatile session, hitting its lowest point in over six months before recovering some losses. The S&P ended the day 0.5% higher at 5,611.85. Despite this, the index is on track for its worst month since September 2022, with a 7% decline in March.
Via Benzinga · March 31, 2025
Shares of biotechnology company Moderna (NASDAQ:MRNA)
fell 12.5% in the morning session after Peter Marks, the head of the FDA's Center for Biologics Evaluation and Research (CBER), resigned on Friday, 28 March 2025. Marks noted his departure was related to "misinformation and lies" around immunization and raised concerns about the Trump administration's ability to "swiftly approve critical vaccines."
Via StockStory · March 31, 2025
Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.
Via Chartmill · March 31, 2025
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Monday.
Via Chartmill · March 31, 2025
Risk sentiment remains under pressure at the start of the week on Wall Street, with tech-heavy indexes sliding while commodities advance, as traders fear a new wave of price pressures following the upcoming tariffs announcement.
Via Benzinga · March 31, 2025
All three major indexes are on track for monthly and quarterly losses.
Via Talk Markets · March 31, 2025
Curious about the market action on Monday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.
Via Chartmill · March 31, 2025
Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on S&P500 stock movements.
Via Chartmill · March 31, 2025
Vaccine stocks are trading lower Monday following a shakeup at the U.S. Food and Drug Administration.
Via Benzinga · March 31, 2025
Peter Marks heads up the department in charge of reviewing vaccines, genetic medicines and cell therapies.
Via Investor's Business Daily · March 31, 2025
Here’s this week’s top 10 worst performing Large-Caps in the last twelve months.
Via Talk Markets · March 27, 2025
Curious about the S&P500 stocks that are in motion on Wednesday? Join us as we explore the top movers within the S&P500 index during today's session.
Via Chartmill · March 26, 2025
Vaccine makers Moderna Inc (NASDAQ:MRNA) and Novavax Inc (NASDAQ:NVAX) are facing selling pressure on Wednesday following reports suggesting the Trump administration will end support for Gavi.
Via Benzinga · March 26, 2025
Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Wednesday. Stay informed about the latest market trends.
Via Chartmill · March 26, 2025
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Moderna (NASDAQ:MRNA) and the best and worst performers in the therapeutics industry.
Via StockStory · March 24, 2025
Large-cap stocks worst performers last week, including BEKE, RDDT, FUTU, JHX, INCY, NUE, BAH, XPEV, MRNA, TU, WLK. Are they in your portfolio?
Via Benzinga · March 23, 2025